Abstract | INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors ( gliptins) occupy a growing place in the armamentarium of drugs used for the management of hyperglycemia in type 2 diabetes, although some safety concerns have been raised in recent years. AREAS COVERED: EXPERT OPINION: The good tolerance/safety profile of DPP-4 inhibitors has been largely confirmed, including in more fragile populations (elderly, renal impairment) with almost no increased risk of infection or gastrointestinal AEs, no weight gain and a minimal risk of hypoglycemia. Although an increased risk of acute pancreatitis and pancreatic cancer was suspected, the complete set of available data appears reassuring so far. Cardiovascular safety of DPP-4 inhibitors has been proven but an unexpected increased risk of heart failure has been reported which should be confirmed in ongoing trials and better understood. Further postmarketing surveillance is recommended.
|
Authors | André J Scheen |
Journal | Expert opinion on drug safety
(Expert Opin Drug Saf)
Vol. 14
Issue 4
Pg. 505-24
(Apr 2015)
ISSN: 1744-764X [Electronic] England |
PMID | 25630605
(Publication Type: Journal Article, Review)
|
Chemical References |
- Dipeptidyl-Peptidase IV Inhibitors
- Hypoglycemic Agents
|
Topics |
- Diabetes Mellitus, Type 2
(drug therapy)
- Dipeptidyl-Peptidase IV Inhibitors
(adverse effects, therapeutic use)
- Humans
- Hyperglycemia
(drug therapy, etiology)
- Hypoglycemia
(chemically induced, epidemiology)
- Hypoglycemic Agents
(adverse effects, therapeutic use)
|